| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-045 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 | 序 | 持有人名称 | 持有数量（股） | 占总股本的比例（%） | | --- | --- | --- | --- | | 1 | 浙江祥云科技股份有限公司 | 144,376,377 | 26.20 | | 2 | 东方证券股份有限公司－中庚价值先锋股票型证券投资 基金 | 21,343,734 | 3.87 | | 3 | 邵君芳 | 16,650,037 | 3.02 | | 4 | 上海诺铁资产管理有限公司－合肥中安海通股权投资基 金合伙企业（有限合伙） | 13,830,500 | 2.51 | | 5 | 浙江花园生物医药股份有限公司－2022 年员工持股计划 | 7,674,790 | 1.39 | | 6 | 香港中央结算有限公司 | 5,426,682 | 0.98 | | 7 | 中科先行（北京）资产管理有限公司 | 5,000,000 | 0.91 | | 8 | #赖大建 | 3,85 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-044 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 经浙江花园生物医药股份有限公司（以下简称"公司"）第六届董事会第十六次会 议审议通过，决定于2023年9月7日（星期四）召开公司2023年第一次临时股东大会。现 将会议相关事项通知如下： 一、会议召开的基本情况 1、股东大会届次：2023年第一次临时股东大会 2、召集人：董事会 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《深圳证券交易 所创业板股票上市规则》等有关法律、法规、部门规章、规范性文件及《公司章程》的 规定。 4、会议召开的日期、时间 （1）现场会议时间：2023年9月7日（星期四）下午14:30； （2）网络投票时间：2023年9月7日；其中，通过深圳证券交易所交易系统进行网络 投票的时间为：2023年9月7日9:15-9:25、9:30-11:3 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-042 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 第六届监事会会第十四次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）第六届监事会第十四次会议 于 2023 年 8 月 22 日在公司会议室以现场方式召开。会议通知于 2023 年 8 月 18 日以微 信及电子邮件等方式送达给全体监事。应出席监事 3 人，实际出席监事 3 人，符合《公 司法》和《公司章程》的有关规定。 会议经审议形成如下决议： 一、审议通过了《关于回购公司部分股份方案的议案》 监事会认为，公司本次回购股份方案符合《公司法》《证券法》《关于支持上市公 司回购股份的意见》《上市公司股份回购规则》等法律法规及《公司章程》等规定，本 次股份回购不会对公司经营活动、财务状况及未来发展产生重大影响，不会影响公司的 上市地位。该事项的决策程序符合相关法律法规和《公司章程》的规定，不存在损害公 司和中小股 ...

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2023-041 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 第六届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）第六届董事会第十六次会议 于2023年8月22日在公司会议室以现场结合通讯表决方式召开。会议通知于2022年8月18 日以微信、电子邮件等方式送达给全体董事。本次会议由公司董事长邵徐君先生召集并 主持，应出席董事9人，实际出席董事9人，公司监事、高管列席了会议。会议符合《公 司法》和《公司章程》的有关规定。 经参会董事表决，审议通过了如下议案： 一、审议通过了《关于回购公司部分股份方案的议案》 （一）回购股份的目的 基于对公司未来发展前景的信心及对公司价值的高度认可，为有效维护广大股东利 益，增强投资者信心，在综合考虑公司的经营状况、财务状况和股票二级市场状况后， 公司拟使用自有资金以集中竞价交易方式回购公司部分股份， ...

Financial Performance - The company's operating revenue for the reporting period was ¥656,743,810.69, a decrease of 17.96% compared to ¥800,552,160.04 in the same period last year[22]. - The net profit attributable to shareholders was ¥117,207,847.77, down 60.54% from ¥297,037,103.38 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥105,610,344.41, a decline of 59.35% compared to ¥259,829,636.24 in the previous year[22]. - The net cash flow from operating activities was ¥136,429,704.54, representing a decrease of 57.78% from ¥323,154,330.91 in the same period last year[22]. - The gross profit margin for the pharmaceutical segment was 74.79%, down 5.62% from the previous year, with revenue declining by 29.95%[54]. - The company's revenue for the reporting period was ¥656,743,810.69, a decrease of 17.96% compared to ¥800,552,160.04 in the same period last year[52]. - The net profit for the first half of 2023 was CNY 117,207,847.77, a decrease of 60% compared to CNY 297,037,103.38 in the same period of 2022[166]. - The total revenue for the first half of 2023 was CNY 656,743,810.69, a decrease of 18% compared to CNY 800,552,160.04 in the same period of 2022[165]. Assets and Liabilities - Total assets at the end of the reporting period increased by 35.63% to ¥5,603,973,301.08 from ¥4,131,859,509.89 at the end of the previous year[22]. - The net assets attributable to shareholders rose by 14.27% to ¥2,939,222,838.92 from ¥2,572,174,931.79 at the end of the previous year[22]. - Total liabilities increased to ¥2,664,750,462.16, up from ¥1,559,684,578.10 at the end of last year[160]. - The company's total liability of CNY 2,059,175,953.45 as of June 30, 2023, compared to CNY 863,162,800.96 at the beginning of the year, indicating a significant increase[164]. Research and Development - Research and development investment increased by 41.08% to ¥47,634,586.43, driven by the strategy to enhance R&D capabilities[52]. - The company has established a stable and sustainable product development pipeline, transitioning from generic drugs to high-end generics with high technical barriers[49]. - The company has entered the registration process for 5 products and has 11 products under research, focusing on cardiovascular, digestive, and neurological systems[41]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new biopharmaceutical products in 2023[68]. - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on innovative drug formulations[136]. Market and Product Development - The company is focusing on the "one vertical and one horizontal" development strategy, increasing R&D investment and enhancing market integration[30]. - The company has identified five key pharmaceutical products for development, responding to market needs and regulatory changes[34]. - The company has three core production processes for Vitamin D3, which have received national awards and are at the international leading level[43]. - The company has completed a strategic acquisition of a smaller biotech firm for 300 million yuan, enhancing its product portfolio and market reach[68]. - New product launches are expected to contribute an additional 100 million yuan in revenue by the end of 2023, with three new products scheduled for release[68]. Strategic Initiatives - The company has built stable long-term strategic partnerships with internationally renowned manufacturers and distributors, enhancing its market channels[47]. - The company has actively responded to provincial procurement tenders, adding 8 new selected provinces for Valsartan Amlodipine Tablets during the reporting period[36]. - The company is considering strategic acquisitions to enhance its product portfolio and market reach[135]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[181]. Risks and Challenges - The company faces risks related to project investments, as uncertainties in construction progress, implementation, and outcomes could impact strategic development and operational scale[79]. - There is a heightened demand for high-quality talent in research, production, sales, and management due to the company's strategic development, which poses risks in management and human resource integration[79]. - The company faces risks from changes in medical reform policies, which could lead to a decline in operating performance if not adapted timely[80]. - There is a risk of declining drug prices due to government efforts to reduce medical costs, potentially impacting the company's profitability as average profit margins in the pharmaceutical industry may decrease[80]. Environmental and Compliance - The company has been recognized as one of the first four key industry environmental "leading" demonstration enterprises in Zhejiang Province[91]. - The company maintains compliance with environmental standards, with all monitored pollutants reported as not exceeding regulatory limits[91]. - The company has established a green development philosophy focusing on source reduction, process control, and end treatment of waste[91]. - The company invested CNY 1.74257 million in environmental governance and protection during the reporting period, and paid CNY 3,753.29 in environmental protection tax[96]. Shareholder Information - The company reported a cash dividend distribution of RMB 1.40 per 10 shares, totaling RMB 77,141,057.98 for the fiscal year 2022[149]. - The employee stock ownership plan includes 119 core management and key employees holding a total of 7,674,790 shares, representing 1.39% of the company's total equity[87]. - The company confirmed a share-based payment expense of approximately CNY 13.68 million for the employee stock ownership plan during the reporting period[88]. - The total number of shares outstanding is 551,007,557, with 98.41% being unrestricted shares[131].

Financial Performance - The company's revenue for Q1 2023 was ¥317,120,309.15, a decrease of 17.97% compared to ¥386,592,882.41 in the same period last year[6] - Net profit attributable to shareholders was ¥51,859,513.29, down 65.69% from ¥151,152,689.96 year-on-year[6] - Operating profit decreased to CNY 55,583,823.97, a decline of 68.7% from CNY 177,090,497.45 in Q1 2022[22] - Basic and diluted earnings per share for Q1 2023 were CNY 0.09, compared to CNY 0.28 in Q1 2022[24] - Total operating revenue for Q1 2023 was CNY 317,120,309.15, a decrease of 17.9% compared to CNY 386,592,882.41 in Q1 2022[22] - Total operating cost for Q1 2023 was CNY 269,882,876.30, up from CNY 234,074,731.77 in the same period last year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 43.11% to ¥139,756,862.80 from ¥245,658,562.83 in the previous year[6] - Cash inflow from operating activities was CNY 488,520,775.06, an increase from CNY 465,917,742.62 in Q1 2022[26] - Total cash outflow from operating activities amounted to CNY 348,763,912.26, up 58.2% from CNY 220,259,179.79 year-on-year[27] - Cash inflow from financing activities reached CNY 1,414,803,000.00, significantly higher than CNY 255,880,000.00 in the previous year, marking a growth of 451.5%[27] - Net cash flow from financing activities was CNY 1,276,076,114.69, an increase of 533.5% compared to CNY 201,208,438.42 in the prior year[27] - The ending balance of cash and cash equivalents was CNY 1,852,183,602.49, up from CNY 731,816,265.22 year-on-year, representing an increase of 153.5%[27] Assets and Liabilities - Total assets increased by 31.55% to ¥5,435,505,587.57 from ¥4,131,859,509.89 at the end of the previous year[6] - Total liabilities rose to CNY 2,491,668,937.63, compared to CNY 1,559,684,578.10 in the previous year[21] - As of March 31, 2023, total current assets reached 2,693,749,556.25 RMB, up from 1,387,028,622.29 RMB at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,685[13] - Zhejiang Xiangyun Technology Co., Ltd. holds 26.20% of shares, amounting to 144,376,377 shares, with 74,600,000 shares pledged[13] - The top ten shareholders hold a combined total of 207,000,000 shares, representing a significant portion of the company's equity[13] Expenses and Costs - The company reported a 74.35% increase in management expenses to ¥36,885,830.24, primarily due to higher equity incentive costs and depreciation[9] - Interest expenses surged by 82.24% to ¥9,315,186.44, attributed to increased costs from convertible bonds[9] - Cash paid for various operating activities rose by 306.72% to ¥99,617,099.13, mainly due to increased marketing expenses[10] - The company paid CNY 59,317,697.09 in taxes, which is an increase of 72.9% compared to CNY 34,329,539.86 last year[27] - Cash paid to employees was CNY 47,089,422.12, an increase of 18.5% from CNY 39,855,621.37 in the previous year[27] Investment and Development - The company has ongoing research and development efforts, as indicated by the increase in development expenditures to 30,209,385.93 RMB from 25,455,115.40 RMB[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[12] - The company plans to expand its market presence through the issuance of convertible bonds and potential new product developments[18] - The company issued 12 million convertible bonds at a face value of 100 RMB each, raising a total of 1.2 billion RMB, with a net amount of 1.186 billion RMB after expenses[18] Inventory and Cash Management - Inventory as of March 31, 2023, was 584,765,776.51 RMB, compared to 545,874,555.66 RMB at the beginning of the year[19] - The cash balance increased to 1,889,045,651.71 RMB from 554,909,447.09 RMB at the beginning of the year[19] Audit Status - The report for the first quarter was not audited[28]

Financial Performance - The company's operating revenue for 2022 was CNY 1,417,511,816.01, representing a 26.89% increase compared to CNY 1,117,099,893.11 in 2021[20]. - The net profit attributable to shareholders decreased by 20.68% to CNY 383,722,581.79 from CNY 479,829,624.81 in the previous year[20]. - The net profit after deducting non-recurring gains and losses increased by 34.66% to CNY 348,567,290.39 compared to CNY 254,918,385.95 in 2021[20]. - The net cash flow from operating activities was CNY 377,039,761.35, down 26.40% from CNY 504,029,922.29 in 2021[20]. - The total assets at the end of 2022 reached CNY 4,131,859,509.89, a 17.05% increase from CNY 3,525,311,449.31 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.68% to CNY 2,572,174,931.79 from CNY 2,278,749,932.36 in 2021[20]. - The company’s total operating revenue for 2022 was ¥1,417,511,816.01, representing a year-on-year increase of 26.89% compared to ¥1,117,099,893.11 in 2021[58]. - The company's net profit attributable to shareholders was ¥383,722,581.79, a decrease of 20.68% from ¥483,766,455.27 in the previous year[56]. Dividend Distribution - The company plans to distribute a cash dividend of 1.40 CNY per 10 shares (including tax) based on a total of 551,007,557 shares[5]. - The company plans to distribute a cash dividend of RMB 1.40 per 10 shares, totaling RMB 77,141,057.98, which represents 20.10% of the net profit for 2022[136]. - The total number of shares for the dividend distribution is based on 551,007,557 shares[135]. - The company confirmed that the cash dividend policy complies with its articles of association and shareholder resolutions[134]. - There are no stock bonuses or share increases planned for this period[135]. Market and Product Development - The company reported a significant focus on the development of new products, particularly in the field of Vitamin D3, which includes various formulations[12]. - The company is actively pursuing market expansion strategies, particularly in the healthcare and nutritional sectors, to enhance its competitive position[12]. - The company emphasizes the importance of innovation in its product offerings, particularly in the pharmaceutical sector, to meet market demands[12]. - The company is focused on enhancing its production capabilities to support the growing demand for its products, particularly in the international markets[12]. - The company has successfully registered multiple products, including valsartan amlodipine tablets and doxofylline injection, which are now included in national procurement programs[34]. - The valsartan amlodipine tablet has been selected in 25 provinces for national procurement, indicating strong market penetration[38]. - The company has completed the layout of the entire vitamin D3 industrial chain, becoming the only global producer with this capability, significantly enhancing its competitive edge[46]. - The company is transitioning from generic drugs to high-tech barrier formulations, focusing on chronic disease areas such as cardiovascular and neurological conditions[52]. Research and Development - The company has three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials, continuously developing new products and optimizing existing processes[43]. - In 2022, the company obtained three drug registration approvals, including Metronidazole tablets and Dexamethasone injection, and has five products under review and nine in development[44]. - Research and development expenses increased by 18.66% to ¥70,343,069.11, compared to ¥59,280,575.57 in 2021[56]. - The company’s R&D investment amounted to ¥83,522,135.46, representing 5.89% of operating revenue, a decrease from 6.14% in 2021[71]. - The number of R&D personnel increased by 16.06% to 159 in 2022, reflecting a commitment to enhancing research capabilities[70]. Risk Management - The company has outlined potential risks in its future development outlook, emphasizing the importance of risk management in its operations[5]. - The company faces significant risks from Vitamin D3 price fluctuations, which have a high impact on revenue due to its substantial contribution to total sales[96]. - Project investment risks are present due to uncertainties in construction progress, implementation, and effectiveness, despite the company's strong technical foundation[96]. - The company is at risk of management and human resource integration challenges as it requires a significant influx of high-quality talent for its strategic development[96]. - The ongoing medical reform in China may alter market competition and operational models, posing a risk to the company's performance if it fails to adapt[97]. - The government’s drug price management policies may lead to a continued downward trend in drug prices, potentially affecting the company's profitability[97]. - The risk of not being selected in centralized drug procurement could adversely impact the sales of certain products if they fall under the procurement scope[97]. Corporate Governance - The company is committed to maintaining high standards of financial reporting and transparency, as evidenced by the involvement of its board and accounting personnel in the annual report[5]. - The company has established a robust governance structure with independent directors and a diverse management team[121]. - The company is committed to optimizing its governance structure and management processes to enhance operational efficiency and digital management levels[95]. - The company maintains a complete and independent operational system, ensuring no interference from the controlling shareholder in its business activities[110]. - The company has a diverse board with members having extensive backgrounds in economics and management[115][116]. Environmental Responsibility - The company has established a comprehensive wastewater treatment system, ensuring effective collection and treatment of various wastewater types[149]. - The company has been recognized as one of the first four key industry environmental "leaders" in Zhejiang Province[149]. - The company holds valid pollution discharge permits, with the latest issued on March 4, 2022, valid until March 3, 2027[147]. - The company employs advanced waste gas treatment technologies, including deep cooling and resin adsorption, to minimize emissions[149]. - The company has implemented a noise control strategy by using low-noise equipment and installing soundproofing devices[150]. - The company has developed emergency response plans for environmental incidents and conducts regular training for employees[151]. - The company adheres to strict environmental protection standards, with all monitored emissions reported to environmental authorities in real-time[150]. - The company emphasizes a green development philosophy, focusing on source reduction, process control, and end treatment of waste[149]. Employee and Management - The company has a total of 849 employees, with 462 in production, 198 in technical roles, and 45 in sales[131]. - The educational background of employees includes 233 with a bachelor's degree or higher, 265 with an associate degree, and 351 with less than an associate degree[131]. - The company has implemented a performance-based compensation system to encourage employees to contribute to profitability and development[132]. - The company’s management team includes experienced professionals with backgrounds in finance, engineering, and human resources[119][120]. - The company has established a comprehensive training system for new employees and ongoing skill development[133]. Strategic Partnerships and Market Presence - The company has established a stable strategic partnership with international manufacturers and distributors, enhancing its market presence and brand recognition in the feed, food, and pharmaceutical industries[50]. - The company has established a comprehensive sales network covering most regions in China, primarily using a "distribution + academic promotion" sales model[42]. - The company is actively involved in the pharmaceutical industry, with key personnel holding significant positions in related associations[115]. Compliance and Legal Matters - The company has not sold any significant assets during the reporting period[90]. - The company has no changes in the use of raised funds or any issues in fund usage disclosure[89]. - The company reported no violations of external guarantees during the reporting period[173]. - There were no major lawsuits or arbitration matters during the reporting period[176]. - The company did not engage in any asset or equity acquisition or sale transactions during the reporting period[180].

Financial Performance - The company's operating revenue for 2022 was ¥1,417,511,816.01, representing a 26.89% increase compared to ¥1,117,099,893.11 in 2021[20]. - The net profit attributable to shareholders decreased by 20.68% to ¥383,722,581.79 from ¥479,829,624.81 in the previous year[20]. - The net profit after deducting non-recurring gains and losses increased by 34.66% to ¥348,567,290.39, up from ¥254,918,385.95 in 2021[20]. - The net cash flow from operating activities was ¥377,039,761.35, a decrease of 26.40% from ¥504,029,922.29 in 2021[20]. - The total assets at the end of 2022 were ¥4,131,859,509.89, reflecting a 17.05% increase from ¥3,525,311,449.31 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.68% to ¥2,572,174,931.79 from ¥2,278,749,932.36 in 2021[20]. - The basic earnings per share decreased by 21.35% to ¥0.70 from ¥0.88 in the previous year[20]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing only ¥29,932,598.25 compared to ¥151,152,689.96 in the first quarter[22]. - The company reported a net cash flow from financing activities surged by 451.01% to ¥43,990,014.48, compared to a net outflow of ¥12,532,243.05 in 2021[74]. Dividend and Shareholder Information - The company reported a total of 551,007,557 shares, with a cash dividend of 1.40 CNY per 10 shares (including tax) for all shareholders[5]. - The company has not proposed any stock bonus distribution, indicating a focus on cash dividends instead[5]. - The cash dividend distribution was executed on May 18, 2022, following the approval at the annual general meeting[135]. - The total number of shares for the dividend distribution is based on 551,007,557 shares[134]. - The company confirmed a shareholding plan involving 119 core management and key employees, holding a total of 7,674,790 shares, which is 1.39% of the total share capital[136]. - The employee stock ownership plan recognized a share-based payment expense of RMB 6,840,858.78 during the reporting period[137]. Research and Development - The company is actively involved in the research and development of innovative drugs, particularly in the vitamin D3 category[12]. - The company has established three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials[43]. - The number of R&D personnel increased by 16.06% to 159 in 2022, reflecting the company's commitment to enhancing its research capabilities[70]. - Research and development expenses increased by 18.66% to ¥70,343,069.11, compared to ¥59,280,575.57 in 2021[56]. - The company is actively pursuing multiple R&D projects aimed at enriching its product line and enhancing market competitiveness, with several projects already approved for market entry[69]. Market and Product Development - The company aims to expand its market presence and enhance product offerings, focusing on the development of new technologies and products in the vitamin D3 segment[12]. - The demand for food and pharmaceutical-grade vitamin D3 has significantly increased due to rising health awareness, with less price volatility compared to feed-grade products[33]. - The company plans to raise 1.2 billion yuan through convertible bonds to support the industrialization of the full-active VD3 project and expand its vitamin product portfolio[35]. - The pharmaceutical segment focuses on high-barrier formulations for chronic diseases, with a strategy aligned with national medical reform policies[34]. - The company has completed the layout of the entire vitamin D3 industry chain, becoming the only global producer with a full industry chain for vitamin D3[46]. Risk Factors - The company has outlined potential risks in its future development outlook, which investors should be aware of[5]. - The company faces significant risks related to Vitamin D3 price fluctuations, as its revenue from Vitamin D3 and similar products constitutes a high proportion of total revenue[95]. - Project investment risks are present due to uncertainties in construction progress, implementation, and effectiveness, despite the company's strong technical foundation[95]. - The ongoing medical reform in China may alter the market competition landscape, posing a risk to the company's operational performance if it fails to adapt[96]. - The government’s efforts to lower drug prices may lead to a continued downward trend in drug prices, negatively impacting the company's profitability[96]. Corporate Governance and Management - The company emphasizes the importance of quality management practices in its production processes, adhering to GMP standards[12]. - The company has established a robust governance structure with independent directors overseeing its strategic direction[120]. - The company maintains a complete and independent operational system, ensuring no interference from the controlling shareholder in its business activities[109]. - The company has a diverse board with members having extensive backgrounds in economics and management[113][114][115]. - The company experienced changes in its board and management, including the resignation of the deputy general manager on January 28, 2022, due to retirement[112]. Environmental Responsibility - The company has established a comprehensive wastewater treatment system, effectively managing various types of wastewater[147]. - The company has been recognized as one of the first four key industry environmental "leading" demonstration enterprises in Zhejiang Province[147]. - The company has implemented a green development philosophy focusing on source reduction, process control, and end treatment of waste[147]. - The company’s emissions for ammonia nitrogen in wastewater were reported at 0.611 mg/l, well below the standard limit of 35 mg/l[145]. - The company has implemented energy-saving machinery to reduce electricity consumption as part of its carbon emission reduction measures[152]. Employee and Social Responsibility - The company adheres to labor laws and pays full social insurance for employees, focusing on their health and satisfaction[155]. - The company is committed to social responsibility, contributing to local economic development and job creation[157]. - The company has established a comprehensive training system, including onboarding, general skills, management skills, and professional skills training programs[132]. - The company implemented a compensation system focused on responsibility, ability, and performance to encourage employees to contribute positively to the company's profitability and development[131]. Strategic Initiatives - The company has a strategic goal of "producing one generation, researching one generation, and reserving one generation" in its pharmaceutical manufacturing sector[44]. - The company emphasizes a strategy of vertical and horizontal development to enhance its innovation capabilities in the pharmaceutical and health sectors[93]. - The company plans to ensure stable production operations and meet customer order demands in 2023[93]. - The company aims to complete the construction of a 6,000 tons vitamin A project and a 200 tons biotin project in 2023 as part of its convertible bond fundraising projects[93].

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-026 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物高科股份有限公司 关于举行 2022 年度业绩网上说明会的公告 （问题征集专题页面二维码） 特此公告。 浙江花园生物高科股份有限公司董事会 2023 年 3 月 27 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江花园生物高科股份有限公司（以下简称"公司"）定于 2023 年 4 月 10 日（星 期一）下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会。本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长邵徐君、董事兼花园药业总经理 方福生、董事会秘书喻铨衡、财务总监吴春华、独立董事邵毅平、保荐代表人郭鑫。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向 投资者公开征集问题，广泛 ...